Strategic Collaborations Potential sales opportunities exist through partnering with Ichor for delivery of DNA drugs and vaccines using the TriGrid system. Target biotech and pharma firms seeking advanced non-viral delivery platforms or plasmid DNA constructs, especially in oncology, infectious diseases, and biodefense.

Small Team Agility Ichor is a privately held, small team (2-10 employees), suggesting a preference for pilot collaborations, rapid decision cycles, and flexible contracting. Outreach should emphasize lightweight engagement, co-development pilots, and clear value reiteration with defined milestones.

Biotech Focus Operating in biotechnology research with emphasis on DNA delivery technologies, TriGrid offers a turnkey platform. Sales angles include enabling rapid testing of plasmid constructs, monoclonal antibodies, and vaccine candidates across multiple disease indications.

Strategic Partnerships Historical and ongoing collaborations with AstraZeneca, Immunomic Therapeutics, and others indicate openness to license deals and research partnerships. Position offerings around co-development, licensing options, and access to TriGrid for clinical-stage programs.

Global Disease Reach TriGrid applicability across cancer, HBV, HIV, Ebola, and biodefense suggests opportunities with multinational teams pursuing diverse targets. Highlight scalable, automated DNA delivery to support diverse clinical programs and rapid iteration in trials.